Literature DB >> 23093636

Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer.

Yves Fradet1.   

Abstract

Entities:  

Year:  2012        PMID： 23093636      PMCID： PMC3478344          DOI： 10.5489/cuaj.12272

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  16 in total

1.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

2.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

3.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

4.  Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.

Authors:  Ashutosh Tewari; George Divine; Peter Chang; M Mendel Shemtov; Matthew Milowsky; David Nanus; Mani Menon
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

5.  13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.

Authors:  Peter C Albertsen; James A Hanley; David F Penson; George Barrows; Judith Fine
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

6.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Authors:  Matthew R Cooperberg; Andrew J Vickers; Jeanette M Broering; Peter R Carroll
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

9.  High-risk prostate cancer in the United States, 1990-2007.

Authors:  Matthew R Cooperberg; Janet Cowan; Jeannette M Broering; Peter R Carroll
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

10.  Substratification of high-risk localised prostate cancer treated by radical prostatectomy.

Authors:  Michele Lodde; François Harel; Louis Lacombe; Yves Fradet
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.